Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 4/20 | 0.32 |
| ▸ | GLA | P06280 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15801520 | 0.83 | GPR84 (0.33) | GPR84HSD17B10 | |
| SCHEMBL2632908 | 0.69 | — | — | |
| SCHEMBL796518 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL9285711 | 0.67 | — | — | |
| SCHEMBL12755333 | 0.66 | PIM1 (0.38) | DAOALDH1A1LMNABLMKDM4E | |
| SCHEMBL12755331 | 0.66 | CHEK1 (0.37) | DAOALDH1A1LMNAPOLBMAPT | |
| SCHEMBL3708688 | 0.66 | GPR84 (0.39) | GPR84ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL2054595 | 0.65 | NOTUM (0.42) | GPR84ALDH1A1MAPTL3MBTL1HPGD | |
| SCHEMBL19935941 | 0.63 | JAK2 (0.43) | GPR84KMT2A | |
| SCHEMBL22244098 | 0.62 | DAO (0.45) | DAOALDH1A1LMNAPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128450-A1 | NLRX1 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-10328065-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-10328065-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-10328066-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-10328066-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | NOVARTIS AG (CH) | 2019-06-25 | — | — | US | disclosed |
| US-20180318275-A1 | COMBINATION THERAPY USING PI3K INHIBITOR AND MDM2 INHIBITOR | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-11-08 | — | — | US | disclosed |
| US-20180256557-A1 | PHARMACEUTICAL COMBINATION COMPRISING (A) THE ALPHA-ISOFORM SPECIFIC PI3K INHIBITOR ALPELISIB (BYL719) AND (B) AN AKT INHIBITOR, PREFERABLY MK-2206, AFURESERTIB OR UPROSERTIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-09-13 | — | — | US | disclosed |
| US-20180243280-A1 | A PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE CDK4/6 INHIBITOR RIBOCICLIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-08-30 | — | — | US | disclosed |
| US-20180243279-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2018-08-30 | — | — | US | disclosed |
| WO-2017037573-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | NOVARTIS AG (CH) | 2017-03-09 | — | — | WO | disclosed |
| WO-2012016970-A1 | A CRYSTALLINE FORM OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-(4 -METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYL-ETHYL)-PYRIDIN-4-YL]-THIAZOL-2-YL)-AMIDE AND ITS USE AS PI3K INHIBITOR | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012016970-A1 | A CRYSTALLINE FORM OF (S)-PYRROLIDINE-1,2-DICARBOXYLIC ACID 2-AMIDE 1-(4 -METHYL-5-[2-(2,2,2-TRIFLUORO-1,1-DIMETHYL-ETHYL)-PYRIDIN-4-YL]-THIAZOL-2-YL)-AMIDE AND ITS USE AS PI3K INHIBITOR | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-2240475-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | Novartis AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105711-A1 | Organic Compounds | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010029082-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, PIK3CA, RICTOR | DAO 4009/4885GPR84 2205/4885ALDH1A1 4645/4885 |
| US-20180243279-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | BRAF, RAF1, PIK3CA | DAO 4145/4885GPR84 4804/4885ALDH1A1 2803/4885 |
| US-20180243280-A1 | A PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE CDK4/6 INHIBITOR RIBOCICLIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | CDK4, CDK3, CDK6 | DAO 4785/4885GPR84 4521/4885ALDH1A1 3287/4885 |
| US-10328066-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the CDK4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer | CDK4, CDK6, CDK9 | DAO 4656/4885GPR84 4626/4885ALDH1A1 3501/4885 |
| US-20100105711-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | DAO 1515/4885GPR84 3554/4885ALDH1A1 1908/4885 |
| US-20230128450-A1 | NLRX1 LIGANDS | NLRP3, NLRP1, NOD1 | DAO 1316/4885GPR84 37/4885ALDH1A1 4043/4885 |
| US-20180318275-A1 | COMBINATION THERAPY USING PI3K INHIBITOR AND MDM2 INHIBITOR | TP53, MDM2, BCL2 | DAO 4462/4885GPR84 4148/4885ALDH1A1 3047/4885 |
| US-20180256557-A1 | PHARMACEUTICAL COMBINATION COMPRISING (A) THE ALPHA-ISOFORM SPECIFIC PI3K INHIBITOR ALPELISIB (BYL719) AND (B) AN AKT INHIBITOR, PREFERABLY MK-2206, AFURESERTIB OR UPROSERTIB, AND THE USE THEREOF IN THE TREATMENT/PREVENTION OF CANCER | PIK3CA, PIK3R5, PIK3R2 | DAO 4458/4885GPR84 4642/4885ALDH1A1 3869/4885 |
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | DAO 1545/4885GPR84 3481/4885ALDH1A1 1680/4885 |
| US-10328065-B2 | Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer | BRAF, RAF1, PIK3CA | DAO 4145/4885GPR84 4804/4885ALDH1A1 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.